Observational studyBMC infectious diseases2026
Efficacy and safety of amphotericin B colloidal dispersion in the treatment of mucormycosis: a real-world observation.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMucormycosis is a medical emergency associated with high morbidity and mortality, primarily affecting immunocompromised individuals. The treatment of mucormycosis remains challenging due to the limited effective antifungal options. This study aimed to assess the real-world efficacy and safety of long-term, low-dose amphotericin B colloidal dispersion (ABCD) in the treatment of mucormycosis.
methodsThis retrospective study at Huashan Hospital included mucormycosis patients treated with ABCD between August 1, 2021, and April 30, 2024. Efficacy and safety were assessed, and prognostic factors for 90-day mortality were identified using a Cox proportional hazards model.
resultsThirty-eight patients were included. Pulmonary mucormycosis was the most common (60.5%) presentation followed by disseminated (23.7%), rhino-orbital (15.8%), and others. The predisposing factors included diabetes mellitus (55.3%), haematological malignancy (23.7%), COVID-19 infection (15.8%), and others. Rhizopus species (11/21, 52.4%) were the most common. ABCD was administered as primary therapy in 27 (71.1%) patients at a median dose of 2.3 mg/kg/day (interquartile range [IQR] 2.0–3.0) for 38 days (IQR 14–71). Seventeen patients (44.7%) received ABCD as salvage therapy, with a median dose of 2.5 mg/kg/day (IQR 1.9–3.1) over 31 days (IQR 22–68). Clinical response rates were 63.0% and 82.4% at the end of ABCD initial and salvage therapy, respectively. Adverse drug reactions occurred in 81.6% of patients, primarily hypokalemia (39.5%, 15/38). The 90-day mortality reached 15.8%. Glucocorticoid use was independently associated with reduced 90-day survival rate (hazard ratios 9.44, 95% confidence interval 1.85–48.32; p = 0.007).
conclusionsLong-term and low-dose use of ABCD had favorable safety and efficacy for both initial and salvage treatment of mucormycosis. Baseline glucocorticoid use was associated with higher 90-day mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.